Older men who find themselves living alone tend to have fewer close personal relationships than older women. They’re ...

This election, the future of health coverage for fertility treatments has been a hot political issue. A new report highlights ...

Alvaro Morata has made a substantial impact at AC Milan already, and yet there are concerns about whether enough goals will ...

Some associates see their position as working to improve both the organization and themselves, while others work simply for ...

A highly effective class of weight loss drug has taken the world by storm, as medications like Ozempic, Wegovy, and Zepbound ...

Compounded semaglutide is semaglutide with an altered formula to create an unbranded alternative to Wegovy and Ozempic.

This hyper-focus on cutting-edge AI and the “next big thing” poses a dilemma for many entrepreneurs: There is more pressure ...

When you think of health care, what do you picture? Many of us see doctors in white coats and nurses wearing scrubs, but we don’t think of the people behind the scenes who ensure everything runs ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Shares in Hims & Hers Health fell after the U.S. Food and Drug Administration said Eli Lilly's obesity and diabetes drugs are no longer in shortage. Shares were down 7% in premarket trading to $17.64.